Trials / Completed
CompletedNCT03284879
Post-Marketing Surveillance Study of OTEZLA
OTEZLA® Tablets Drug Use-Results Survey
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,086 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica 1. Planned registration period 2 years 2. Planned surveillance period for 4 years from 6 months after launch
Conditions
Timeline
- Start date
- 2017-09-05
- Primary completion
- 2021-10-31
- Completion
- 2022-03-20
- First posted
- 2017-09-15
- Last updated
- 2025-09-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03284879. Inclusion in this directory is not an endorsement.